The global intravenous immunoglobulin market size was estimated at USD 8,820.44 Million in 2017 and is anticipated to gain significant traction over coming years.
Immunoglobulin denotes the analysis of blood plasma containing antibody. Intravenous Immunoglobulin (IVIG) is a product which is administered intravenously. IVIG comprises polyvalent IgG antibodies that are extracted from a number of blood donor’s plasma. In general, the intravenous immunoglobulin treatment is given to the individuals who are suffering from common variable immunodeficiency due to the insufficient amount of antibodies such as X-linked agammaglobulinemia (XLA), Wiskott Aldrich Syndrome, and other forms of hypogammaglobulinemia. This treatment aids patient by maintaining the proper amount of antibodies in the body.
The global intravenous immunoglobulin market is driven by increasing occurrence of immunodeficiency. For instance, according to one industry reports, acquired immunodeficiency is a type of congenital immunodeficiency. Moreover, approximately 50,000 new cases of congenital immunodeficiency are diagnosed in the U.S. each year. In addition, according to the World Health Organization (WHO) 2016, approximately 36.7 million people are living with HIV globally. Thus, increasing prevalence of such cases demanding appropriate treatment and upsurge in the use of immunoglobulins to treat inflammatory myopathies, GuillainBarre syndrome or specific antibody deficiency is anticipated to boost the market growth. Additionally, the rise in the authorization of intravenous immunoglobulin (IVIG) drugs from the government as well as organizations such as European Medicine Agency (EMA), and Food and Drug Administration (FDA) is anticipated to boost the sales of immunoglobulin. Growing in the elderly population and developed IVIG production due to the development of technological advancement are the other key factors that contributing to the intravenous immunoglobulin market growth.
However, strict government policies and high cost associated with the therapy, and side effects with the use of IVIG are factors hampering the market growth.
The global Intravenous Immunoglobulin Market is segmented on the basis of Application and geography. On the basis of application, the global Intravenous Immunoglobulin Market is categorized into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Multifocal motor neuropathy, Myasthenia Gravis, Chronic Lymphocytic Leukemia, Kawasaki disease, Guillain-Barre syndrome, and Idiopathic Thrombocytopenic Purpura (ITP).
In 2017, Hypogammaglobulinemia is estimated to dominate the application segment. The dominance is attributed to the growing global occurrences of primary immunodeficiency diseases (PID). It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). According to the Centers for Disease Control and Prevention (CDC) in 2012, the global occurrence rate of hypogammaglobulinemia was around 2 per 100,000 populations moreover, the number of people suffering this type of disease is estimated to increase during the forecast period. Growing occurrence of immunodeficiency disorders associated with the high implementation of IVIG therapies is expected to drive the segment growth significantly.
In terms of geography, North America is estimated to dominate the global Intravenous Immunoglobulin Market. Increasing healthcare expenditure, growing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and rising inclination of clinicians towards immunodeficiency therapies are the key factors attributing towards the market growth. Rising elderly population and changing lifestyle susceptible to chronic diseases are some of the factors contributing to the growth the intravenous immunoglobulin market growth in this region. Additionally, growing occurrences of primary immunodeficiency (PID) is anticipated to enhance the market growth in North America. According to American Autoimmune Related Disease Association Inc. (AARDA) 2012, approximately 50 million Americans were diagnosed to have autoimmune diseases and the number of people suffering this disease is expected to increase during the forecast period further bolstering the market growth.
Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Intravenous Immunoglobulin Market are Baxter International Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare among others.